Avecure Flexible Microwave Ablation Probe For Lung Nodules

Lung Cancer Clinical Trial

Official title: Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule

Status Recruiting

Clinical Trial Summary

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.

This research study involves microwave ablation (MWA)

Clinical Trial Description

This will be a single arm, prospective cohort study.

The names of the study intervention involved in this study is:

• Cone Beam Computed Tomography (CBCT)-guided electromagnetic navigational bronchoscopy (ENB) microwave ablation (MWA)

• A rapid on-site evaluation (ROSE) will be performed before the MWA to confirm that the lesion is malignant, this can lead to longer procedure time and time under anesthesia.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

• Participants will receive the study intervention and will be followed for 30 days.

• It is expected that about 10 people will take part in this research study.

This research study is a Pilot Study, which is the first-time investigators are examining this intervention using a bronchoscopic approach for microwave ablation of solitary pulmonary nodules.

The U.S. Food and Drug Administration (FDA) has approved this intervention as a treatment option for this disease. ;

Related Conditions & MeSH terms

• Lung Cancer
• Lung Cancer Stage I
• Lung Cancer Stage II
• Lung Neoplasms
• Stage I Lung Cancer
• Stage II Lung Cancer

• NCT number: NCT05281237
• Study type: Interventional
• Source: Beth Israel Deaconess Medical Center
• Contact: Jason Beattie, MD
• Phone: (617) 632- 8252
• Email: jbeattie@bidmc.harvard.edu
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2022
• Completion date: June 30, 2025